JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression

Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐cooperating signaling pathways or cancer hallmarks, such as tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohrherr, Julian, Haber, Marcel, Breitenecker, Kristina, Aigner, Petra, Moritsch, Stefan, Voronin, Viktor, Eferl, Robert, Moriggl, Richard, Stoiber, Dagmar, Győrffy, Balázs, Brcic, Luka, László, Viktória, Döme, Balázs, Moldvay, Judit, Dezső, Katalin, Bilban, Martin, Popper, Helmut, Moll, Herwig P., Casanova, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856680/
https://www.ncbi.nlm.nih.gov/pubmed/31407334
http://dx.doi.org/10.1002/ijc.32624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856680/
https://www.ncbi.nlm.nih.gov/pubmed/31407334
http://dx.doi.org/10.1002/ijc.32624

Ejemplares similares